MYGN - Myriad Genetics, Inc.
| Previous Close | 23.05 |
| Open | 23.02 |
| Bid | 22.30 x 1800 |
| Ask | 22.48 x 3200 |
| Day's Range | 22.32 - 23.36 |
| 52 Week Range | 22.07 - 50.44 |
| Volume | 1,107,244 |
| Avg. Volume | 1,437,581 |
| Market Cap | 1.526B |
| Beta (3Y Monthly) | 1.40 |
| PE Ratio (TTM) | 374.83 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Thomson Reuters StreetEvents
Edited Transcript of MYGN earnings conference call or presentation 13-Aug-19 8:30pm GMT
Q4 2019 Myriad Genetics Inc Earnings Call
- Benzinga
Barron's Picks And Pans: American Eagle Outfitters, Chevron, Grocery Outlet And More
The cover story in this weekend's Barron's offers stock picks for an energy sector rebound. Other featured articles discuss how the trade war is hitting tech's bottom line and why banks are not an alternative ...
- Barrons.com
Myriad Genetics Stock Has an F.D.A. Issue
A test that Myriad is counting on to restore sales growth is in trouble with the U.S. Food and Drug Administration.
- Motley Fool
Myriad Genetics Limps Into Fiscal 2020
A sluggish end to fiscal 2019 and weaker-than-expected guidance for the year ahead aren't instilling much confidence in investors.
- Simply Wall St.
Myriad Genetics (NASDAQ:MYGN) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- Motley Fool
Why Myriad Genetics, Nordstrom, and Luckin Coffee Slumped Today
Different challenges hit these companies but led to the same result.
- Investor's Business Daily
Why This Genetic-Testing Outlet Just Wiped Out Its 26% Breakout Gain
Myriad Genetics stock crashed Wednesday after the genetic-testing outlet unveiled new reimbursement challenges, dampening its 2020 outlook. Shares wiped out their gains after a breakout.
- Motley Fool
Here's Why Myriad Genetics Is Getting Crushed Today
The genetic testing company reported fiscal 2019 operating results and told investors that regulators want changes to an important product.
- MarketWatch
Myriad Genetics stock plummets 39% after lower-than-expected earnings, FDA questions
Shares of molecular-diagnostics firm Myriad Genetics Inc. plummeted 39% Wednesday morning after the company reported lower-than-expected fourth-quarter earnings and disclosed that the U.S. Food and Drug Administration had requested changes to one of its tests. On Tuesday afternoon, Myriad reported a fourth-quarter loss of $4.2 million, or 6 cents a share, after reporting earnings of $14.5 million, or 20 cents a share, in the year-earlier quarter. Adjusted EPS for the latest quarter was 41 cents a share, below the FactSet consensus of 47 cents a share. Revenue fell 11% to $215.4 million, missing the FactSet consensus of $221.6 million and the company's previous fourth-quarter guidance of $220 million. "Unfortunately, revenue in the fourth quarter was two percent below expectations largely due to lower reimbursement for our expanded carrier screening test," said Myriad CEO Mark Capone in a statement. Myriad said in its 10-K that the FDA had requested changes to its GeneSight test. The company said it has submitted a proposal they believe addresses the FDA's principal concerns. The GeneSight test is meant to analyze how a patient's genes may affect their response to depression drugs. UnitedHealth said in August that it would cover the test for members, sending Myriad's stock soaring. Shares of Myriad have now fallen 7.2% so far this year, while the S&P 500 has gained 14.9%.
- Zacks
Myriad Genetics (MYGN) Q4 Earnings Lag Estimates, Revenues Up
Myriad Genetics' (MYGN) overall Q4 performance is impressive, excepting weak sales at a few segments.
- Barrons.com
Myriad Genetics Stock Craters on Weak Earnings and FDA Scrutiny
Shares of the molecular-diagnostic biotech firm were down 30.4% after the company reported financial results that missed expectations and it said the FDA had “requested changes” to GeneSight.
- Motley Fool
What You'll Want to Know About Myriad Genetics' Disappointing Q4 Results
There wasn't much to like with the molecular diagnostics company's latest quarterly update.
- TheStreet.com
Myriad Genetics Sinks on Fourth-Quarter Earnings and Revenue Miss
Myriad Genetics tumbles after missing Wall Street's fiscal fourth-quarter earnings and revenue expectations.
Motley FoolMyriad Genetics Inc (MYGN) Q4 2019 Earnings Call Transcript
MYGN earnings call for the period ending June 30, 2019.
- Zacks
Myriad Genetics (MYGN) Lags Q4 Earnings and Revenue Estimates
Myriad (MYGN) delivered earnings and revenue surprises of -12.77% and -2.81%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Investor's Business Daily
Will This Medical Stock Sacrifice Its Breakout On A Wide Quarterly Miss?
Myriad Genetics stock plunged late Tuesday after the genetic testing outfit lagged Wall Street's quarterly forecasts and issued light guidance for 2020. The stock recently broke out.
- Benzinga
Myriad Genetics Q4 Earnings Preview
Myriad Genetics (NASDAQ: MYGN ) announces its next round of earnings this Tuesday, August 13. Here's Benzinga's look at Myriad Genetics's Q4 earnings report. Earnings and Revenue Based on Myriad Genetics ...
- Zacks
Can Cannabis Therapy Drive Canopy Growth's (CGC) Q1 Earnings?
Canopy Growth (CGC) expects to deliver a strong first-quarter fiscal 2020 on solid performance by its cannabis therapy business.
- Zacks
What's in the Offing for Cisco Systems' (CSCO) Q4 Earnings?
Cisco (CSCO) is benefiting from its expanding footprint in the rapidly growing security market. Also, partnerships and synergies from acquisitions will boost the company's revenue base.
- GuruFocus.com
Tieton Capital Management, LLC Buys Myriad Genetics Inc, Sells Atlas Financial Holdings Inc, ...
Yakima, WA, based Investment company Tieton Capital Management, LLC (Current Portfolio) buys Myriad Genetics Inc, sells Atlas Financial Holdings Inc, Helix Energy Solutions Group Inc, Stabilis Energy Inc during the 3-months ended 2019Q2, according to the most recent filings of the investment company, Tieton Capital Management, LLC. Continue reading...
- GuruFocus.com
Myriad Genetics Inc (MYGN) CFO Richard Bryan Riggsbee Sold $1 million of Shares
CFO of Myriad Genetics Inc (30-Year Financial, Insider Trades) Richard Bryan Riggsbee (insider trades) sold 25,000 shares of MYGN on 08/01/2019 at an average price of $41.5 a share. Continue reading...
- Market Realist
Myriad Genetics Up after UnitedHealth’s Favorable Decision
Yesterday, Myriad Genetics submitted an 8K filing with the SEC announcing a favorable coverage decision by UnitedHealth Group.
- Motley Fool
Why SunPower, Myriad Genetics, and Cirrus Logic Jumped Today
Find out how these stocks stayed higher even after a big plunge in the broader market.
- Investor's Business Daily
Genetic Testing: Medical Stock Ramps 50% On Insurance Coverage
Myriad Genetics stock launched to a 10-month high Thursday after UnitedHealth Group decided to provide insurance coverage for its genetic testing kit, GeneSight, in depression and anxiety.
- Motley Fool
Here's Why Myriad Genetics Is Soaring Today
A major insurer agreed to cover one of the company's most important genetic tests.
